NgoMeyi 19, 2022, Ulawulo lweeMveliso zonyango lwaseTshayina (NMPA) lwamkele isicelo sentengiso ye-Bayer's Vericiguat (2.5 mg, 5 mg, kunye ne-10 mg) phantsi kwegama lebrendi Verquvo™.
Eli chiza lisetyenziselwa izigulane zabantu abadala abaneempawu zokungaphumeleli kwentliziyo kunye nokunciphisa i-fraction ye-ejection (i-ejection fraction <45%) ezizinziswe emva kwesiganeko sokutshatyalaliswa kwamva nje kunye nonyango lwe-intravenous, ukunciphisa umngcipheko wokulaliswa esibhedlele ngenxa yokungaphumeleli kwentliziyo okanye unyango oluphuthumayo lwe-diuretic.
Ukuvunywa kwe-Vericiguat kwakusekelwe kwiziphumo ezilungileyo ezivela kwisifundo se-VICTORIA, esibonise ukuba i-Vericiguat inokunciphisa ngakumbi umngcipheko wokufa kwe-cardiovascular death kunye nokulaliswa esibhedlele ngenxa yokungaphumeleli kwentliziyo nge-4.2% (isiganeko sokunciphisa umngcipheko ngokupheleleyo / iminyaka eyi-100 yesigulane) kwizigulane ezinentliziyo. Ukungaphumeleli oye waba nesiganeko sokutshatyalaliswa kwentliziyo yamva nje kwaye bezinzile kunyango lwe-intravenous kunye nokunciphisa i-fraction ejection (iqhezu le-ejection <45%).
NgoJanuwari 2021, I-Vericiguat yavunywa e-United States yonyango lwe-symptomatic heart failure kwizigulane ezineejection fraction ngaphantsi kwe-45% emva kokufumana isiganeko esibi sentliziyo.
Ngo-Agasti ka-2021, isicelo esitsha seziyobisi se-Vericiguat samkelwa yi-CDE kwaye emva koko sibandakanyiwe kuhlaziyo oluphambili kunye nenkqubo yokuvunywa ngenxa yezizathu "zeziyobisi ezingxamisekileyo zeklinikhi, amayeza amatsha kunye nokuphucula amachiza amatsha okuthintela kunye nokunyangwa kwezifo ezithathelwanayo kunye nezifo ezinqabileyo" .
Ngo-Epreli ka-2022, I-2022 AHA / ACC / HFSA Isikhokelo soLawulo lweNtliziyo yeNtliziyo, ekhutshwe ngokubambisana yi-American College of Cardiology (ACC), i-American Heart Association (AHA), kunye ne-Heart Failure Society of America (HFSA), ihlaziywe. unyango lwe-pharmacologic lokungaphumeleli kwentliziyo kunye nokunciphisa i-ejection fraction (HFrEF) kwaye iquka i-Vericiguat kwiziyobisi ezisetyenziselwa unyango lwezigulane ezinomngcipheko ophezulu we-HFrEF kunye nokunyanzeliswa kweentliziyo ezisekelwe kunyango oluqhelekileyo.
I-Vericiguat yi-sGC (i-soluble guanylate cyclase) isivuseleli esinenoveli indlela ephuhliswe ngokudibeneyo yi-Bayer kunye ne-Merck Sharp & ne-Dohme (MSD).Inokungenelela ngokuthe ngqo kwi-cell-signaling mechanism disorder kunye nokulungisa indlela ye-NO-sGC-cGMP.
Izifundo zangaphambi kweklinikhi kunye nekliniki zibonise ukuba i-NO-soluble guanylate cyclase (sGC) -cyclic guanosine monophosphate (cGMP) indlela yokubonisa indlela yokubonakalisa eyona nto inokuthi ijoliswe kuyo ekuqhubeni kwentliziyo engapheliyo kunye nokunyangwa kwentliziyo.Ngaphantsi kweemeko ze-physiological, le ndlela yomqondiso yindlela ephambili yokulawula i-myocardial mechanics, umsebenzi we-cardiac, kunye ne-vascular endothelial function.
Ngaphantsi kweemeko ze-pathophysiological zokungaphumeleli kwentliziyo, ukunyuka kokuvuvukala kunye nokungasebenzi kwe-vascular kunciphisa i-NO bioavailability kunye ne-lowstream cGMP synthesis.Ukunqongophala kwe-cGMP kukhokelela kwi-dysregulation ye-vascular tension, i-vascular and cardiac sclerosis, i-fibrosis kunye ne-hypertrophy, kunye ne-coronary kunye ne-renal microcirculatory dysfunction, ngaloo ndlela ikhokelela ekuqhubeni kokwenzakala kwe-myocardial, ukunyuka kokuvuvukala kunye nokuhla ngakumbi ekusebenzeni kwentliziyo kunye nezintso.
Ixesha lokuposa: May-19-2022